It is with great pleasure that we present the sixth Latin American Forum on Biosimilars (FLAB 2016), and the seventh Brazilian Forum on Biosimilars. This event on 29 and 30 June will bring us together in Brasília once again and feature a comprehensive schedule covering the main topics related to the future of biosimilar drugs in Latin America.
Over 500 local and international visitors are scheduled to attend the forum, including health professionals, researchers, and representatives of patient associations, government agencies, the pharmaceutical industry, and regulating bodies from Brazil and Latin America, among others.
Since its first edition, FLAB has promoted debates, basic and clinical education, and the creation of new perspectives on biosimilars. For 2016, the scientific commission has organized a thoroughly structured program around current and highly relevant topics. The organizing team itself was restructured, and now enjoys support from new and important specialists in the area.
There is no doubt that the commercialization of new biosimilar drugs gives rise to broad regulatory, scientific, and marketing debates, as well as educational ones. The general theme of the forum this year is: Clinical and Security Data of Biosimilars in Latin America.
Hard work on the part of the organizers since the first editions of the event has granted a maturity to FLAB, which in its 2016 edition has attained unquestionable status as the largest and most important Latin American event on biosimilars. Attendees have been witnesses to the progress seen on both organizational and program quality levels.
We hope that all participants will actively take advantage of all this event has to offer. FLAB 2016 was especially designed for you to initiate or expand your knowledge on this subject while strengthening your network.
Best regards and welcome to FLAB 2016!
The Organizing Committee, FLAB 2016